Inactive Instrument

Curetis N.V.

Equities

Advanced Medical Equipment & Technology

Curetis N.V. Reports Earnings Results for the Full Year Ended December 31, 2019

July 01, 2020 at 02:08 pm EDT

Curetis N.V. Announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was EUR 1.050 million compared to EUR 734,000 a year ago. Net loss was EUR 24.486 million compared to EUR 23.745 million a year ago. Basic loss per share was EUR 1.05 compared to EUR 1.4 a year ago.

Latest news about Curetis N.V.

Curetis N.V. Reports Earnings Results for the Full Year Ended December 31, 2019	20-07-01	CI
Curetis N.V. Auditor Raises 'Going Concern' Doubt	20-06-30	CI
Curetis N.V. Informs on Delay of Publication of Audited Financial Year 2019 Financial Results and Annual Report	20-04-30	CI
Curetis N.V. Announces Board Resignations	20-04-01	CI
Curetis N.V. and Quaphaco Enters into Unyvero Distribution Partnership for Vietnam	20-02-06	CI
Curetis N.V. Launches Unyvero LRT Panel for BAL Specimens in the U.S	20-01-14	CI
Curetis N.V. Receives U.S. FDA 510(K) Clearance of Unyvero LRT for Bal Specimens	19-12-20	CI
Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens	19-11-25	CI
Curetis N.V. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-11-25	CI
Curetis Ag Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-18	CI
Transcript : Curetis N.V., OpGen, Inc. - M&A Call	19-09-04
OpGen, Inc. and Curetis N.V. Announces Executive Changes	19-09-04	CI
OpGen, Inc. entered into a definitive agreement to acquire Curetis AG from Curetis N.V. for $13.2 million.	19-09-03	CI
OpGen, Inc. completed the acquisition of Curetis AG (“Curetis”) from Curetis N.V..	19-09-03	CI
Curetis Retains H.C. Wainwright & Co. As Strategic Advisor	19-08-12	CI
Curetis and AKO MED Ink Distribution Agreement Covering Four Countries in CEE Region	19-07-30	CI
Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens	19-07-23	CI
Curetis N.V. Announces New Data on its Unyvero System and LRT Application Cartridge for Pneumonia	19-06-04	CI
Curetis N.V. Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples	19-05-23	CI
Curetis N.V. to Receive Additional EUR 5 Million Financing from EIB	19-05-21	CI
Curetis N.V. announced that it has received €21.5 million in funding from Yorkville Advisors Global LP	19-05-20	CI
Curetis N.V. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-17	CI
Certain Ordinary Shares of Curetis N.V. are subject to a Lock-Up Agreement Ending on 8-MAY-2019.	19-05-07	CI
Curetis N.V Reports Consolidated Earnings Results for the Full Year Ended December 31, 2018; Provides Revenue Guidance for 2019	19-04-11	CI
Curetis N.V. Auditor Raises 'Going Concern' Doubt	19-04-10	CI

Chart Curetis N.V.

Duration

Period

More charts

Company Profile

Curetis specializes in the development and marketing of molecular diagnostic systems for hospitals and laboratories. The products are devoted to detecting severe infectious diseases as well as resistance to anti-biotics in hospitalized patients. The diagnostic solutions (Unyvero Solution) enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. Syndromic tests for diagnosing lower respiratory tract infections /pneumonia as well as implant and tissue infections are commercially available.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
SARTORIUS AG	-12.91%	19.08B
QUIDELORTHO CORPORATION	-46.21%	2.65B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+18.15%	1.87B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-3.12%	1.61B
BIOTAGE AB	+23.78%	1.21B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-10.69%	1.02B
CONTEC MEDICAL SYSTEMS CO.,LTD	-20.89%	905M
REVENIO GROUP OYJ	-7.14%	716M
VAREX IMAGING CORPORATION	-18.10%	682M

Medical Diagnostic & Testing Equipment